James A. Leal - 27 Sep 2021 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role: SVP, Operations
Signature: s/ David B. Berger, Attorney-in-Fact for James A. Leal
Issuer symbol: TNDM
Transactions as of: 27 Sep 2021
Net transactions value: -$20,987
Form type: 4
Filing time: 29 Sep 2021, 16:46:57 UTC
Previous filing: 09 Sep 2021
Next filing: 28 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNDM	Common Stock	Options Exercise	$85,850	+1,667	+44%	$51.50	5,418	27 Sep 2021	Direct	F1
transaction	TNDM	Common Stock	Options Exercise	$19,597	+238	+4.4%	$82.34	5,656	27 Sep 2021	Direct	F1
transaction	TNDM	Common Stock	Sale	$79,253	-660	-12%	$120.08	4,996	27 Sep 2021	Direct	F2, F3
transaction	TNDM	Common Stock	Sale	$24,520	-201	-4%	$121.99	4,795	27 Sep 2021	Direct	F2, F4
transaction	TNDM	Common Stock	Sale	$128,109	-1,044	-22%	$122.71	3,751	27 Sep 2021	Direct	F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNDM	Stock Option	Options Exercise	$85,850	+1,667	+6.3%	$51.50	28,333	27 Sep 2021	Common Stock	1,667	$51.50	Direct	F6, F7
transaction	TNDM	Stock Option	Options Exercise	$19,597	+238	+3.2%	$82.34	7,624	27 Sep 2021	Common Stock	238	$82.34	Direct	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon exercise of a stock option award.
F2	The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020.
F3	The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $120.00 to $120.63. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F4	The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $121.04 to $122.03. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F5	The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $122.18 to $122.93. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F6	The options vested as to twenty-five (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
F7	The expiration date for these options is 10 years from the date of grant.
F8	The options vested as to twenty-five (25%) of the underlying shares on 5/27/2021, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the 2013 Plan.